Imagine a continent where cholera outbreaks could be fought with locally-made vaccines, no longer reliant on distant suppliers. This vision is closer than ever as South Africa embarks on a groundbreaking journey. This week marks the launch of a clinical trial for the first African-developed cholera vaccine, a potential game-changer in the fight against this deadly disease. But here's where it gets controversial: can Africa truly break free from the global vaccine supply chain, and what does this mean for the future of healthcare on the continent?
South Africa’s Biovac Institute is leading the charge with an oral cholera vaccine, developed in partnership with the International Vaccine Institute in South Korea. This collaboration, established in 2022, represents a significant step toward self-sufficiency in vaccine production. Currently, the global supply of cholera vaccines is monopolized by EuBiologics in South Korea, whose Euvichol-Plus vaccine is the only option available. This monopoly has led to severe shortages and rationing, particularly as cholera outbreaks surge worldwide, fueled by climate crises and conflicts, especially in Africa.
Biovac’s Phase 1 safety trial, conducted at the University of the Witwatersrand in Johannesburg, is a critical first step. If successful, the vaccine will advance to a larger Phase 3 study, where it will be compared directly to Euvichol-Plus. Dr. Morena Makhoana, Biovac’s CEO, proudly emphasized that this vaccine is being manufactured entirely in South Africa—a milestone not achieved in over fifty years. Biovac has transformed from a vaccine distributor into a full-scale manufacturing hub, capable of producing vaccines from start to finish, rather than relying on imported components for the final stages.
And this is the part most people miss: If the trials succeed, South Africa will become the first African nation to produce a cholera vaccine, addressing a critical need amid global shortages. The vaccine could be approved and ready for use by 2028, depending on trial outcomes. This development is not just about cholera; it’s about enhancing Africa’s health security and sovereignty.
South African Health Minister Dr. Aaron Motsoaledi hailed the trial as a historic milestone, not just for South Africa but for the entire continent. He stressed that local vaccine manufacturing is a necessity, not a luxury. It reduces vulnerability to supply chain disruptions, geopolitical pressures, and vaccine nationalism—issues that became glaringly apparent during the COVID-19 pandemic. The African Union’s ambitious goal is for 60% of all routine vaccines used in Africa to be manufactured on the continent by 2030, a massive leap from today’s less than 1%.
Gavi, the Vaccine Alliance, is playing a pivotal role by offering incentives for African-made vaccines, positioning Biovac as a frontrunner in the market. Gavi’s African Vaccine Manufacturing Accelerator (AVMA) will invest up to $1 billion over the next decade to bolster Africa’s medicines and vaccines manufacturing base. The Biovac project is also supported by major funders like the Gates Foundation, Open Philanthropy, Wellcome, and the ELMA Vaccines & Immunization Foundation.
Florian von Groote, Wellcome’s head of clinical research for infectious diseases, highlighted the trial’s potential to strengthen Africa’s vaccine manufacturing landscape. “Through long-term support and investment, local manufacturing can deliver accessible and affordable vaccines made by Africa, for Africa,” he said. This initiative could set a precedent for other vaccine developments, ensuring that African communities have timely access to life-saving treatments.
But here’s the question that sparks debate: Will this shift toward local manufacturing truly democratize access to vaccines, or will it create new challenges in quality control, distribution, and affordability? As Africa takes this bold step toward self-reliance, the world watches with anticipation. What do you think? Is this the future of global health, or are there pitfalls we’re not yet considering? Share your thoughts in the comments below.
Image Credits: WHO (https://www.afro.who.int/news/ministry-health-support-who-and-partners-vaccinated-over-63-000-people-oral-cholera-vaccine).
Join us in combating the infodemic in health information and supporting evidence-based health policy reporting from the global South. Our network of journalists in Africa, Asia, Geneva, and New York connects regional realities to global debates. To contribute, click here on PayPal.
